Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 234Lung Neoplasms 106Ovarian Neoplasms 81Breast Neoplasms 81Fallopian Tube Neoplasms 51Small Cell Lung Carcinoma 42Neoplasms 41Triple Negative Breast Neoplasms 31Squamous Cell Carcinoma of Head and Neck 31Head and Neck Neoplasms 25Adenocarcinoma of Lung 25Parkinson Disease 4, Autosomal Dominant Lewy Body 24Carcinoma 23Neoplasm Metastasis 20Carcinoma, Ovarian Epithelial 18Melanoma 14Lymphoma, Large B-Cell, Diffuse 14Carcinoma, Squamous Cell 14Brain Neoplasms 14Prostatic Neoplasms 13Recurrence 12Lymphoma 12Endometrial Neoplasms 12Adenocarcinoma, Bronchiolo-Alveolar 12Esophageal Neoplasms 11Lymphoma, Non-Hodgkin 10Hodgkin Disease 10Brenner Tumor 10Urinary Bladder Neoplasms 9Central Nervous System Neoplasms 9

Interventions

olaparib 1enfortumab vedotin 1Oxaliplatin 1Nivolumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Metastatic Urothelial Cancer × Carboplatin × Clear all
NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡